Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Industry Electronic computers
Sub-IndustryHealth Care Technology
SectorMedical
SymbolNASDAQ:OMCL
CUSIP68213N10
Phone650-251-6100
Debt
Debt-to-Equity Ratio0.33
Current Ratio1.68
Quick Ratio1.22
Price-To-Earnings
Trailing P/E Ratio287.50
Forward P/E Ratio37.50
P/E Growth2.38
Sales & Book Value
Annual Sales$716.16 million
Price / Sales2.81
Cash Flow$1.5884 per share
Price / Cash32.58
Book Value$13.64 per share
Price / Book3.79
Profitability
EPS (Most Recent Fiscal Year)$0.18
Net Income$20.60 million
Net Margins4.55%
Return on Equity4.11%
Return on Assets2.15%
Miscellaneous
Employees2,350
Outstanding Shares38,880,000
Omnicell (NASDAQ:OMCL) Frequently Asked Questions
What is Omnicell's stock symbol?
Omnicell trades on the NASDAQ under the ticker symbol "OMCL."
How were Omnicell's earnings last quarter?
Omnicell, Inc. (NASDAQ:OMCL) posted its quarterly earnings data on Thursday, April, 26th. The company reported $0.29 EPS for the quarter, beating the Zacks' consensus estimate of $0.25 by $0.04. The business had revenue of $182.60 million for the quarter, compared to analyst estimates of $177.49 million. Omnicell had a net margin of 4.55% and a return on equity of 4.11%. The business's revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter last year, the business earned $0.06 earnings per share. View Omnicell's Earnings History.
When is Omnicell's next earnings date?
What guidance has Omnicell issued on next quarter's earnings?
Omnicell updated its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share guidance of $1.85-$2.05 for the period, compared to the Thomson Reuters consensus estimate of $1.97. The company issued revenue guidance of $780-$800 million, compared to the consensus revenue estimate of $790.31 million.Omnicell also updated its Q2 guidance to $0.36-$0.42 EPS.
What price target have analysts set for OMCL?
6 brokers have issued 12 month target prices for Omnicell's shares. Their forecasts range from $44.00 to $67.00. On average, they expect Omnicell's share price to reach $56.6667 in the next year. View Analyst Ratings for Omnicell.
What are Wall Street analysts saying about Omnicell stock?
Here are some recent quotes from research analysts about Omnicell stock:
- 1. Cantor Fitzgerald analysts commented, "On Monday, April 2, CNBC.com reported that Walmart and perhaps Amazon were looking to acquire PillPack." (4/3/2018)
- 2. According to Zacks Investment Research, "Omnicell’s fourth-quarter 2017 performance was impressive with year-over-year increase in both earnings and revenues. Further, both of the company’s segments witnessed year-over-year growth. We are encouraged to note that the company is working on product innovation through R&D. The company is expected to gain from its recent launches and strategic partnerships. Its recent product launches include the XR2 Automated Central Pharmacy System and the IVX Workflow, IVX Workflow creates a significant technological advancement for sterile compounding workflow processes, enabling pharmacies to safely and efficiently compound and prepare IV doses.Also, improvement in margin is also encouraging. However, a tough competitive landscape acts as a dampener. Over the past month, Omnicell’s shares have been trading below the broader industry." (2/2/2018)
Who are some of Omnicell's key competitors?
Who are Omnicell's key executives?
Omnicell's management team includes the folowing people:
- Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 61)
- Mr. Peter J. Kuipers, Exec. VP & CFO (Age 46)
- Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 54)
- Mr. Robin G. Seim, Pres of Global Automation & Medication Adherence (Age 58)
- Mr. Joseph Brian Spears, VP of Corp. Fin. & Chief Accounting Officer (Age 58)
Has Omnicell been receiving favorable news coverage?
Media stories about OMCL stock have been trending positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Omnicell earned a news sentiment score of 0.41 on Accern's scale. They also assigned news stories about the company an impact score of 47.43 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Omnicell's major shareholders?
Omnicell's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.56%), Dimensional Fund Advisors LP (3.96%), Champlain Investment Partners LLC (3.87%), Eagle Asset Management Inc. (3.31%), Royal Bank of Canada (1.96%) and Westwood Holdings Group Inc. (1.67%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Sara J White. View Institutional Ownership Trends for Omnicell.
Which major investors are selling Omnicell stock?
OMCL stock was sold by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Russell Investments Group Ltd., Oak Ridge Investments LLC, Mesirow Financial Investment Management Equity Management, Westfield Capital Management Co. LP, Fisher Asset Management LLC, Eagle Asset Management Inc. and JPMorgan Chase & Co.. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, Jorge R Taborga, Peter J Kuipers, Randall A Lipps and Robin Gene Seim. View Insider Buying and Selling for Omnicell.
Which major investors are buying Omnicell stock?
OMCL stock was bought by a variety of institutional investors in the last quarter, including Rockefeller Capital Management L.P., Penn Capital Management Co. Inc., Intrinsic Edge Capital Management LLC, Westwood Holdings Group Inc., New York State Common Retirement Fund, Fort Washington Investment Advisors Inc. OH, Global Alpha Capital Management Ltd. and Sio Capital Management LLC. View Insider Buying and Selling for Omnicell.
How do I buy shares of Omnicell?
Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Omnicell's stock price today?
One share of OMCL stock can currently be purchased for approximately $51.75.
How big of a company is Omnicell?
Omnicell has a market capitalization of $2.01 billion and generates $716.16 million in revenue each year. The company earns $20.60 million in net income (profit) each year or $0.18 on an earnings per share basis. Omnicell employs 2,350 workers across the globe.
How can I contact Omnicell?
Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]
MarketBeat Community Rating for Omnicell (OMCL)
MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote "Outperform" if you believe OMCL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMCL will underperform the S&P 500 over the long term. You may vote once every thirty days.
